Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Yeka 2007 UGA (Continued)<br />
Free of other bias? Yes No other sources of bias identified<br />
Zongo 2005 BFA<br />
Methods Trial design: A randomized controlled trial<br />
Follow up: A standardized history, examination, and malaria film on days 0, 1, 2, 3, 7,<br />
14, 21, 28, or any other day they felt unwell. Haemoglobin measured on days 0 and 28<br />
or day of clinical failure. Children with Hb < 10 g/dl were treated with ferrous sulphate<br />
and antihelminthic treatment.<br />
Adverse event monitoring: Assessed at each visit<br />
Participants Number: 580 randomized<br />
Inclusion criteria: Age > 6 months, weight > 5 kg, axillary temp > 37.5 ºC or history of<br />
fever in the last 24 hours, P. falciparum mono-infection 2000-200,000/µl, the ability to<br />
participate in 28 days follow up, in<strong>for</strong>med consent<br />
Exclusion criteria: Danger signs or signs of severe malaria, history of serious adverse<br />
effects related to study meds, evidence of concomitant febrile illness, antimalarial use<br />
other than chloroquine in previous 2 weeks, haemoglobin < 5 g/dl<br />
Interventions 1. Artemether-Lumefantrine, fixed dose <strong>combination</strong>, 20 mg/120 mg tablets (Coartem:<br />
Novartis)<br />
• 5 to 14 kg 1 tablet twice daily <strong>for</strong> 3 days<br />
• 15 to 24 kg 2 tablets twice daily <strong>for</strong> 3 days<br />
• 25 to 34 kg 3 tablets twice daily <strong>for</strong> 3 days<br />
• > 35 kg 4 tablets twice daily <strong>for</strong> 3 days<br />
2. Amodiaquine plus sulfadoxine-pyrimethamine, loose <strong>combination</strong> (Amodiaquine:<br />
Aventis, Fansidar: Roche)<br />
• AQ 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2<br />
• SP 25/1.25 mg/kg on day 0<br />
Placebos were used to simulate equal numbers of pills. All doses supervized.<br />
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted<br />
2. Gametocyte carriage assessed weekly<br />
3. Changes in haemoglobin during follow up<br />
4. Adverse events<br />
Not included in the review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
Notes Country: Burkina Faso<br />
Setting: Urban health centres<br />
Transmission: Holoendemic with transmission peaks during the rainy season<br />
Resistance: Not stated<br />
Dates: Aug 2005 to Dec 2005<br />
Funding: Fogarty International Centre of the National Institutes of Health, International<br />
Atomic Energy Agency, National Budget of the Institut de Recherche en Sciences de la<br />
Sante<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
103